Sige Gutman was quoted in Endpoints News about SCOTUS’ unanimous decision siding with Hikma in a closely watched “skinny label” case and its implications for generic drugmakers.

Sige’s “take-home message”: “If you are doing things that are consistent with industry standards, and you're really not making statements or acting in a way that encourages someone to infringe, then you're going to be okay.”

Source

Endpoint News